Bionyra Pharma launches with €143M Series A
Bionyra Pharma launched with a €143M Series A to advance biologics for immune-mediated inflammatory diseases.
European biotech is still attracting serious capital when the science, assets and clinical focus are clear. Bionyra Pharma is launching with one of the larger recent rounds in the sector.
What happened
Bionyra Pharma, a Paris and Boston-based clinical-stage biopharma company, launched with an oversubscribed €143M Series A.
The company is developing biologics for immune-mediated inflammatory diseases, with backing from specialist life sciences investors and strategic healthcare investors.
Why it matters
This is a major European biotech funding signal.
Large Series A rounds in biopharma usually suggest investors see a defined clinical opportunity, not just an early research idea. Immunology and inflammatory disease remain attractive areas because patient needs are large and many conditions still lack strong treatment options.
The bigger picture
Even as broader venture funding stays selective, biotech can still command large rounds when the company has serious science, experienced investors and a clear path into clinical development.